Prof John Seymour
Honorary (Professorial Fellow)
Department of Medicine
1175 Scholarly works
9 Projects
HIGHLIGHTS
2023
Research grants (ARC, NHMRC, MRFF)
PRECISION\2013 Pharmacogenomic Medicines Optimisation for People With Cancer
2022
Journal article
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
DOI: 10.1182/blood.20220160402022
Journal article
Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance
DOI: 10.1182/bloodadvances.20220083252022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752021
Journal article
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
DOI: 10.1182/bloodadvances.20210050832021
Journal article
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy
DOI: 10.1182/blood.20200095782020
Research grants (other domestic)
Exercise Oncology Services Closer to Home: Improving Equity of Access and Survivor Outcome S Through the Development of a Multi-Disciplinary Digitally-Delivered Service.
RECENT SCHOLARLY WORKS
2026
Journal article
Occupational exposure to radiofrequency electromagnetic fields and risk of follicular lymphoma: Family case-control study
DOI: 10.1016/j.canep.2026.1032332026
Journal article
Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia
DOI: 10.1182/bloodadvances.20260207892026
Journal article
Diagnosis and Management of Chronic Lymphocytic Leukemia with TP53 Loss of Function in the Novel Agent Era.
DOI: 10.1182/blood.20260332932026
Journal article
VEN-IBR in older and TP53-mt MCL: have sympathy for SYMPATICO
DOI: 10.1182/blood.20260352032026
Journal article
POSTER: MDS-824: Elritercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent–Naïve Adults With Lower-Risk Myelodysplastic Syndromes and Transfusion-Dependent Anemia: The Elrise MDS Phase 3 Study
DOI: 10.1016/s2152-2650(26)00869-42026
Journal article
Beyond MURANO: sequencing therapy in relapsed chronic lymphocytic leukaemia
DOI: 10.1016/S0140-6736(26)01370-X2026
Journal article
MDS-824: Elritercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent–Naïve Adults With Lower-Risk Myelodysplastic Syndromes and Transfusion-Dependent Anemia: The Elrise MDS Phase 3 Study
DOI: 10.1016/s2152-2650(26)02251-22026
Journal article
ORAL ABSTRACT: IBCL-1332: Phase 3 Results From the EPCORE FL-1 Trial of Epcoritamab (E) With Lenalidomide and Rituximab (R2) Versus R2 for Relapsed or Refractory Follicular Lymphoma (R/R FL)
DOI: 10.1016/s2152-2650(26)00363-0